Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies

Part # PS334

Abstract

Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies. Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via TCR/CD3 or TCR/CD3 plus CD28 co-stimulation.